Conference Coverage
Conference Coverage
SCLC: Bispecific antibody shows phase 1 promise
The antibody targets delta-like ligand 3, which is one of few surface markers for small cell lung cancer.
Conference Coverage
Surgical de-escalation passes clinical test in low-risk cervical cancer
‘Practice-changing’ results could reduce long-term survivor effects among qualifying patients.
Conference Coverage
Groundbreaking new regimen for advanced Hodgkin lymphoma
The immune checkpoint inhibitor nivolumab affords unprecedented improvement in “harmonizing” treatment for adult and pediatric Hodgkin lymphoma...
Conference Coverage
Minimally invasive vs. open surgery in pancreatic cancer
The results from this trial “will help both surgeons and patients feel comfortable that minimally invasive surgery, in expert hands, is not...
Conference Coverage
Unprecedented drop seen in early colorectal cancer cases due to aspirin use
The study confirms evidence from 30 years of research that suggests regular aspirin use reduces cancer risk.
Conference Coverage
'Paradigm shift’: Luspatercept for MDS
In a first head-to-head comparison study, luspatercept for MDS significantly outperformed epoetin alfa in reducing transfusion dependence.
Conference Coverage
Circulating tumor DNA may predict poor prognosis in breast cancer
Detection of ctDNA at any time point was associated with worse overall and disease-free survival in early breast cancer patients.
Conference Coverage
Breast cancer outcomes are worse for Black men
Black Americans are more likely to be diagnosed at older ages and to die from the disease.
Conference Coverage
Urology groups endorse two prostate biopsy approaches
“If you step out of the echo chamber, what you’ll find is that the accurate complications amongst the two procedures are not that dramatically...
Conference Coverage
Breast cancer survivors need a comprehensive care plan, says doctor
Survivor care for cancer patients should address physical and psychological symptoms through an integrated model, expert says.
Conference Coverage
PARP inhibitors and breast cancer: Questions remain about wider use
Oncologists are still trying to understand the best drug targets and the value of combo treatments.